(Q33779856)

29 July 2017

1 reference

title

Luteinizing hormone-releasing hormone analogs: their impact on the control of tumorigenesis (English)

1 reference

29 July 2017

1

Schally AV

1 reference

29 July 2017

publication date

1 January 1999

1 reference

29 July 2017

number of pages

16

1 reference

inferred from page(s)

published in

Peptides

1 reference

29 July 2017

volume

20

1 reference

29 July 2017

issue

10

1 reference

29 July 2017

page(s)

1247-1262

1 reference

Zoladex: a sustained-release, monthly luteinizing hormone-releasing hormone analogue for the treatment of advanced prostate cancer

29 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0196-9781%2899%2900130-8

7 January 2021

Comparison of different doses of gonadotropin-releasing hormone antagonist Cetrorelix during controlled ovarian hyperstimulation

1 reference

https://api.crossref.org/works/10.1016%2FS0196-9781%2899%2900130-8

7 January 2021

Induction of ovulation with D-Trp6-LHRH combined with purified FSH in patients with polycystic ovarian disease

1 reference

https://api.crossref.org/works/10.1016%2FS0196-9781%2899%2900130-8

7 January 2021

Structure of the porcine LH- and FSH-releasing hormone. II. Confirmation of the proposed structure by conventional sequential analyses

1 reference

https://api.crossref.org/works/10.1016%2FS0196-9781%2899%2900130-8

7 January 2021

New antagonists of LHRH. II. Inhibition and potentiation of LHRH by closely related analogues.

1 reference

https://api.crossref.org/works/10.1016%2FS0196-9781%2899%2900130-8

7 January 2021

Highly potent analogues of luteinizing hormone-releasing hormone containing D-phenylalanine nitrogen mustard in position 6.

1 reference

https://api.crossref.org/works/10.1016%2FS0196-9781%2899%2900130-8

7 January 2021

Sustained suppression of serum LH, FSH and testosterone and increase of high-density lipoprotein cholesterol by daily injections of the GnRH antagonist cetrorelix over 8 days in normal men

1 reference

https://api.crossref.org/works/10.1016%2FS0196-9781%2899%2900130-8

7 January 2021

Depot gonadotropin-releasing hormone agonist blunts the androgen-induced suppression of spermatogenesis in a clinical trial of male contraception

1 reference

https://api.crossref.org/works/10.1016%2FS0196-9781%2899%2900130-8

7 January 2021

Hypophysial Responses to Continuous and Intermittent Delivery of Hypothalamic Gonadotropin-Releasing Hormone

1 reference

https://api.crossref.org/works/10.1016%2FS0196-9781%2899%2900130-8

7 January 2021

Intranasal gonadotropin-releasing hormone agonist as a contraceptive agent

1 reference

https://api.crossref.org/works/10.1016%2FS0196-9781%2899%2900130-8

7 January 2021

Hormonal effects of gonadotropin-releasing hormone (GnRH) agonist in the human male. III. Effects of long term combined treatment with GnRH agonist and androgen

1 reference

https://api.crossref.org/works/10.1016%2FS0196-9781%2899%2900130-8

7 January 2021

Treatment of advanced refractory ovarian carcinoma with a gonadotropin-releasing hormone analogue.

1 reference

https://api.crossref.org/works/10.1016%2FS0196-9781%2899%2900130-8

7 January 2021

Primary structure of the ovine hypothalamic luteinizing hormone-releasing factor (LRF) (LH-hypothalamus-LRF-gas chromatography-mass spectrometry-decapeptide-Edman degradation).

1 reference

https://api.crossref.org/works/10.1016%2FS0196-9781%2899%2900130-8

7 January 2021

Steroid secretion in polycystic ovarian disease after ovarian suppression by a long-acting gonadotropin-releasing hormone agonist

1 reference

https://api.crossref.org/works/10.1016%2FS0196-9781%2899%2900130-8

7 January 2021

Efficacy and safety of luteinizing hormone-releasing hormone antagonist cetrorelix in the treatment of symptomatic benign prostatic hyperplasia.

1 reference

https://api.crossref.org/works/10.1016%2FS0196-9781%2899%2900130-8

7 January 2021

Luteinizing hormone-releasing hormone analog treatment of boys with hypothalamic hamartoma and true precocious puberty

1 reference

https://api.crossref.org/works/10.1016%2FS0196-9781%2899%2900130-8

7 January 2021

Gonadotropin-releasing hormone and its analogues

1 reference

https://api.crossref.org/works/10.1016%2FS0196-9781%2899%2900130-8

7 January 2021

Analogs of luteinizing hormone-releasing hormone with increased biological activity produced by D-amino acid substitutions in position 6

1 reference

https://api.crossref.org/works/10.1016%2FS0196-9781%2899%2900130-8

7 January 2021

Hormonal therapy of prostatic carcinoma. Defining the challenge.

1 reference

https://api.crossref.org/works/10.1016%2FS0196-9781%2899%2900130-8

7 January 2021

A controlled trial of leuprolide with and without flutamide in prostatic carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0196-9781%2899%2900130-8

7 January 2021

Therapeutic use of pituitary desensitization with a long-acting lhrh agonist: a potential new treatment for idiopathic precocious puberty

1 reference

https://api.crossref.org/works/10.1016%2FS0196-9781%2899%2900130-8

7 January 2021

Suppression of the endogenous luteinizing hormone surge by the gonadotrophin-releasing hormone antagonist Cetrorelix during ovarian stimulation

1 reference

https://api.crossref.org/works/10.1016%2FS0196-9781%2899%2900130-8

7 January 2021

Gonadotropin-Releasing Hormone (GnRH)-Binding Sites in Human Breast Cancer Cell Lines and Inhibitory Effects of GnRH Antagonists*

1 reference

https://api.crossref.org/works/10.1016%2FS0196-9781%2899%2900130-8

7 January 2021

Effects of LHRH-analogues on mitogenic signal transduction in cancer cells

1 reference

https://api.crossref.org/works/10.1016%2FS0196-9781%2899%2900130-8

7 January 2021

Growth-inhibitory actions of analogues of Luteinizing Hormone Releasing Hormone on tumor cells

1 reference

https://api.crossref.org/works/10.1016%2FS0196-9781%2899%2900130-8

7 January 2021

Luteinizing hormone-releasing hormone agonist triptorelin in combination with cytotoxic chemotherapy in patients with advanced ovarian carcinoma. A prospective double blind randomized trial. Decapeptyl Ovarian Cancer Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0196-9781%2899%2900130-8

7 January 2021

Gonadotropin releasing hormone binding sites in human epithelial ovarian carcinomata

1 reference

https://api.crossref.org/works/10.1016%2FS0196-9781%2899%2900130-8

7 January 2021

Characteristics and distribution of receptors for [D-TRP6]-luteinizing hormone-releasing hormone, somatostatin, epidermal growth factor, and sex steroids in 500 biopsy samples of human breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0196-9781%2899%2900130-8

7 January 2021

Treatment of uterine fibroids with a slow-release formulation of the gonadotrophin releasing hormone antagonist Cetrorelix

1 reference

https://api.crossref.org/works/10.1016%2FS0196-9781%2899%2900130-8

7 January 2021

Polycystic ovary syndrome: abnormalities and management with pulsatile gonadotropin-releasing hormone and gonadotropin-releasing hormone analogs

1 reference

https://api.crossref.org/works/10.1016%2FS0196-9781%2899%2900130-8

7 January 2021

A conservative approach to the management of uterine leiomyoma: pituitary desensitization by a luteinizing hormone-releasing hormone analogue

1 reference

https://api.crossref.org/works/10.1016%2FS0196-9781%2899%2900130-8

7 January 2021

Treatment of duct carcinoma of the pancreas with the LH-RH analogue buserelin

1 reference

https://api.crossref.org/works/10.1016%2FS0196-9781%2899%2900130-8

7 January 2021

Some analogs of luteinizing hormone releasing hormone (LH-RH) having intense ovulation-inducing activity

1 reference

https://api.crossref.org/works/10.1016%2FS0196-9781%2899%2900130-8

7 January 2021

Effect of a GnRH analogue (leuprolide) on benign prostatic hypertrophy

1 reference

https://api.crossref.org/works/10.1016%2FS0196-9781%2899%2900130-8

7 January 2021

Treatment of uterine leiomyomas with luteinizing hormone-releasing hormone antagonist Cetrorelix

1 reference

https://api.crossref.org/works/10.1016%2FS0196-9781%2899%2900130-8

7 January 2021

Influence of D-Trp-6-LH-RH on the survival time in patients with advanced pancreatic cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0196-9781%2899%2900130-8

7 January 2021

Suppression of gonadotrophin release in many by an inhibitory analogue of L.H.-releasing hormone

1 reference

https://api.crossref.org/works/10.1016%2FS0196-9781%2899%2900130-8

7 January 2021

Luteinizing hormone-releasing hormone antagonist cetrorelix as primary single therapy in patients with advanced prostatic cancer and paraplegia due to metastatic invasion of spinal cord

1 reference

https://api.crossref.org/works/10.1016%2FS0196-9781%2899%2900130-8

7 January 2021

Inhibition of luteinizing hormone, follicle-stimulating hormone and sex-steroid levels in men and women with a potent antagonist analog of luteinizing hormone-releasing hormone, Cetrorelix (SB-75)

1 reference

https://api.crossref.org/works/10.1016%2FS0196-9781%2899%2900130-8

7 January 2021

Responses to the antagonistic analog of LH-RH (SB-75, Cetrorelix) in patients with benign prostatic hyperplasia and prostatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0196-9781%2899%2900130-8

7 January 2021

Inhibition of ovulation by intranasal nafarelin, a new superactive agonist of GnRH

1 reference

https://api.crossref.org/works/10.1016%2FS0196-9781%2899%2900130-8

7 January 2021

Flare-up of endometriosis induced by gonadotropin-releasing hormone agonist leading to bowel obstruction

1 reference

https://api.crossref.org/works/10.1016%2FS0196-9781%2899%2900130-8

7 January 2021

Cytotoxic analogs of luteinizing hormone-releasing hormone bind with high affinity to human breast cancers

1 reference

https://api.crossref.org/works/10.1016%2FS0196-9781%2899%2900130-8

7 January 2021

Use of a gonadotropin-releasing hormone antagonist as a physiologic probe in polycystic ovary syndrome: assessment of neuroendocrine and androgen dynamics

1 reference

https://api.crossref.org/works/10.1016%2FS0196-9781%2899%2900130-8

7 January 2021

Shrinkage of a uterine fibroid after subcutaneous infusion of a LHRH agonist

1 reference

https://api.crossref.org/works/10.1016%2FS0196-9781%2899%2900130-8

7 January 2021

Male contraception; synergism of gonadotropin-releasing hormone analog and testosterone in suppressing gonadotropin

1 reference

https://api.crossref.org/works/10.1016%2FS0196-9781%2899%2900130-8

7 January 2021

Administration of nasal nafarelin as compared with oral danazol for endometriosis. A multicenter double-blind comparative clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS0196-9781%2899%2900130-8

7 January 2021

First established pregnancy after controlled ovarian hyperstimulation with recombinant follicle stimulating hormone and the gonadotrophin-releasing hormone antagonist ganirelix (Org 37462)

1 reference

https://api.crossref.org/works/10.1016%2FS0196-9781%2899%2900130-8

7 January 2021

Betidamino acid scan of the GnRH antagonist acyline

1 reference

https://api.crossref.org/works/10.1016%2FS0196-9781%2899%2900130-8

7 January 2021

Delay of puberty and inhibition of reproductive processes in the rat by a gonadotropin-releasing hormone agonist analog

1 reference

https://api.crossref.org/works/10.1016%2FS0196-9781%2899%2900130-8

7 January 2021

Luteinizing hormone-releasing hormone antagonist Cetrorelix (SB-75) and bombesin antagonist RC-3940-II inhibit the growth of androgen-independent PC-3 prostate cancer in nude mice

1 reference

https://api.crossref.org/works/10.1016%2FS0196-9781%2899%2900130-8

7 January 2021

Inhibition of growth of androgen-independent DU-145 prostate cancer in vivo by luteinising hormone-releasing hormone antagonist Cetrorelix and bombesin antagonists RC-3940-II and RC-3950-II.

1 reference

https://api.crossref.org/works/10.1016%2FS0196-9781%2899%2900130-8

7 January 2021

Inhibition of the growth of Caki-I human renal adenocarcinoma in vivo by luteinizing hormone-releasing hormone antagonist Cetrorelix, somatostatin analog RC-160, and bombesin antagonist RC-3940-II.

1 reference

https://api.crossref.org/works/10.1016%2FS0196-9781%2899%2900130-8

7 January 2021

Complete regression of MX-1 human breast carcinoma xenografts after targeted chemotherapy with a cytotoxic analog of luteinizing hormone-releasing hormone, AN-207

1 reference

https://api.crossref.org/works/10.1016%2FS0196-9781%2899%2900130-8

7 January 2021

Molecular structure of the human gonadotropin-releasing hormone receptor gene

1 reference

https://api.crossref.org/works/10.1016%2FS0196-9781%2899%2900130-8

7 January 2021

The nucleotide sequences of human GnRH receptors in breast and ovarian tumors are identical with that found in pituitary

1 reference

https://api.crossref.org/works/10.1016%2FS0196-9781%2899%2900130-8

7 January 2021

Suppression of gonadotropin secretion by a long-acting gonadotropin-releasing hormone analog (leuprolide acetate, Lupron Depot) in children with precocious puberty

1 reference

https://api.crossref.org/works/10.1016%2FS0196-9781%2899%2900130-8

7 January 2021

Gonadotropin-releasing hormone analog design. Structure-function studies toward the development of agonists and antagonists: rationale and perspective

1 reference

https://api.crossref.org/works/10.1016%2FS0196-9781%2899%2900130-8

7 January 2021

Stimulation of LH Release in Men and Women by LH-Releasing Hormone Purified from Porcine Hypothalami

1 reference

https://api.crossref.org/works/10.1016%2FS0196-9781%2899%2900130-8

7 January 2021

Goserelin, a depot gonadotrophin-releasing hormone agonist in the treatment of premenopausal patients with metastatic breast cancer. German Zoladex Trial Group

1 reference

https://api.crossref.org/works/10.1016%2FS0196-9781%2899%2900130-8

7 January 2021

Treatment of precocious puberty with LHRH analogue in combination with cyproterone acetate-further experience

1 reference

https://api.crossref.org/works/10.1016%2FS0196-9781%2899%2900130-8

7 January 2021

Regulation of endometrial cancer cell growth by insulin-like growth factors and the luteinizing hormone-releasing hormone antagonist SB-75.

1 reference

https://api.crossref.org/works/10.1016%2FS0196-9781%2899%2900130-8

7 January 2021

Treatment with a luteinising-hormone-releasing-hormone analogue (buserelin) in premenopausal patients with metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0196-9781%2899%2900130-8

7 January 2021

Hormonal responses to the new potent GnRH antagonist Cetrorelix

1 reference

https://api.crossref.org/works/10.1016%2FS0196-9781%2899%2900130-8

7 January 2021

Targeted cytotoxic analog of luteinizing hormone-releasing hormone AN-207 inhibits the growth of PC-82 human prostate cancer in nude mice

1 reference

https://api.crossref.org/works/10.1016%2FS0196-9781%2899%2900130-8

7 January 2021

Inhibition of growth of experimental prostate cancer with sustained delivery systems (microcapsules and microgranules) of the luteinizing hormone-releasing hormone antagonist SB-75.

1 reference

https://api.crossref.org/works/10.1016%2FS0196-9781%2899%2900130-8

7 January 2021

Prevention of the Transient Adverse Effects of a Gonadotropin-Releasing Hormone Analogue (Buserelin) in Metastatic Prostatic Carcinoma by Administration of an Antiandrogen (Nilutamide)

1 reference

https://api.crossref.org/works/10.1016%2FS0196-9781%2899%2900130-8

7 January 2021

Flutamide Eliminates the Risk of Disease Flare in Prostatic Cancer Patients Treated with a Luteinizing Hormone-Releasing Hormone Agonist

1 reference

https://api.crossref.org/works/10.1016%2FS0196-9781%2899%2900130-8

7 January 2021

Gonadotropin and alpha-subunit secretion during long term pituitary suppression by D-Trp6-luteinizing hormone-releasing hormone microcapsules as treatment of precocious puberty

1 reference

https://api.crossref.org/works/10.1016%2FS0196-9781%2899%2900130-8

7 January 2021

Luteinizing hormone-releasing hormone (LH-RH) antagonist Cetrorelix inhibits growth of DU-145 human androgen-independent prostate carcinoma in nude mice and suppresses the levels and mRNA expression of IGF-II in tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0196-9781%2899%2900130-8

7 January 2021

Growth hormone-releasing hormone antagonist MZ-5-156 inhibits growth of DU-145 human androgen-independent prostate carcinoma in nude mice and suppresses the levels and mRNA expression of insulin-like growth factor II in tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0196-9781%2899%2900130-8

7 January 2021

Potential new treatment of endometriosis: reversible inhibition of pituitary-ovarian function by chronic intranasal administration of a luteinizing hormone-releasing hormone (LH-RH) agonist

1 reference

https://api.crossref.org/works/10.1016%2FS0196-9781%2899%2900130-8

7 January 2021

A single injection of a gonadotropin-releasing hormone (GnRH) antagonist (Cetrorelix) postpones the luteinizing hormone (LH) surge: further evidence for the role of GnRH during the LH surge

1 reference

https://api.crossref.org/works/10.1016%2FS0196-9781%2899%2900130-8

7 January 2021

Antiproliferative effects of luteinizing hormone-releasing hormone agonists on the human prostatic cancer cell line LNCaP

1 reference

https://api.crossref.org/works/10.1016%2FS0196-9781%2899%2900130-8

7 January 2021

Reversible inhibition of testicular steroidogenesis and spermatogenesis by a potent gonadotropin-releasing hormone agonist in normal men: an approach toward the development of a male contraceptive

1 reference

https://api.crossref.org/works/10.1016%2FS0196-9781%2899%2900130-8

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0196-9781%2899%2900130-8

7 January 2021

Regression of leiomyomata uteri following hypoestrogenism induced by repetitive luteinizing hormone-releasing hormone agonist treatment: preliminary report

1 reference

https://api.crossref.org/works/10.1016%2FS0196-9781%2899%2900130-8

7 January 2021

Treatment of breast cancer with gonadotropin-releasing hormone

1 reference

https://api.crossref.org/works/10.1016%2FS0196-9781%2899%2900130-8

7 January 2021

Changes in growth and serum growth hormone and plasma somatomedin-C levels during suppression of gonadal sex steroid secretion in girls with central precocious puberty

1 reference

https://api.crossref.org/works/10.1016%2FS0196-9781%2899%2900130-8

7 January 2021

Phase II trial with D-Trp-6-LH-RH in prostatic carcinoma: comparison with other hormonal agents

1 reference

https://api.crossref.org/works/10.1016%2FS0196-9781%2899%2900130-8

7 January 2021

Synthesis of the porcine LH- and FSH-releasing hormone by the solid-phase method

1 reference

https://api.crossref.org/works/10.1016%2FS0196-9781%2899%2900130-8

7 January 2021

Structure of the porcine LH- and FSH-releasing hormone. I. The proposed amino acid sequence

1 reference

https://api.crossref.org/works/10.1016%2FS0196-9781%2899%2900130-8

7 January 2021

"Medical oophorectomy" using a long-acting GNRH agonist--a possible new approach to the treatment of endometriosis

1 reference

https://api.crossref.org/works/10.1016%2FS0196-9781%2899%2900130-8

7 January 2021

Growth of human breast cancer cells inhibited by a luteinizing hormone-releasing hormone agonist

1 reference

https://api.crossref.org/works/10.1016%2FS0196-9781%2899%2900130-8

7 January 2021

Growth inhibition of human ovarian cancers by cytotoxic analogues of luteinizing hormone-releasing hormone

1 reference

https://api.crossref.org/works/10.1016%2FS0196-9781%2899%2900130-8

7 January 2021

Targeted cytotoxic analog of luteinizing hormone-releasing hormone AN-207 inhibits growth of OV-1063 human epithelial ovarian cancers in nude mice

1 reference

https://api.crossref.org/works/10.1016%2FS0196-9781%2899%2900130-8

7 January 2021

Fibrocystic disease of the breast in premenopausal women: histohormonal correlation and response to luteinizing hormone releasing hormone analog treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0196-9781%2899%2900130-8

7 January 2021

Cytotoxic analogs of luteinizing hormone-releasing hormone containing doxorubicin or 2-pyrrolinodoxorubicin, a derivative 500-1000 times more potent

1 reference

https://api.crossref.org/works/10.1016%2FS0196-9781%2899%2900130-8

7 January 2021

Signal transduction mechanisms of Ca2+ mobilizing hormones: the case of gonadotropin-releasing hormone

1 reference

https://api.crossref.org/works/10.1016%2FS0196-9781%2899%2900130-8

7 January 2021

Suppression of follicular phase pituitary-gonadal function by a potent new gonadotropin-releasing hormone antagonist with reduced histamine-releasing properties (ganirelix).

1 reference

https://api.crossref.org/works/10.1016%2FS0196-9781%2899%2900130-8

7 January 2021

Inhibition of ovulation in women by chronic treatment with a stimulatory lrh analogue — A new approach to birth control?

1 reference

https://api.crossref.org/works/10.1016%2FS0196-9781%2899%2900130-8

7 January 2021

The single or dual administration of the gonadotropin-releasing hormone antagonist Cetrorelix in an in vitro fertilization-embryo transfer program.

1 reference

https://api.crossref.org/works/10.1016%2FS0196-9781%2899%2900130-8

7 January 2021

Response to D-Trp-6-luteinising hormone releasing hormone (Decapeptyl) microcapsules in advanced ovarian cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0196-9781%2899%2900130-8

7 January 2021

Phase III studies to compare goserelin (Zoladex) with orchiectomy and with diethylstilbestrol in treatment of prostatic carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0196-9781%2899%2900130-8

7 January 2021

Treatment of leiomyomata uteri with D-Trp6-luteinizing hormone-releasing hormone

1 reference

https://api.crossref.org/works/10.1016%2FS0196-9781%2899%2900130-8

7 January 2021

The effect of nafarelin acetate, a luteinizing-hormone-releasing hormone agonist, on benign prostatic hyperplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0196-9781%2899%2900130-8

7 January 2021

Chronic administration of the luteinizing hormone-releasing hormone (LHRH) antagonist cetrorelix decreases gonadotrope responsiveness and pituitary LHRH receptor messenger ribonucleic acid levels in rats

1 reference

https://api.crossref.org/works/10.1016%2FS0196-9781%2899%2900130-8

7 January 2021

Remission of postmenopausal breast cancer during treatment with the luteinising hormone releasing hormone agonist ICI 118630

1 reference

https://api.crossref.org/works/10.1016%2FS0196-9781%2899%2900130-8

7 January 2021

Induction of ovulation for in-vitro fertilisation using buserelin and gonadotropins

1 reference

https://api.crossref.org/works/10.1016%2FS0196-9781%2899%2900130-8

7 January 2021

Primary structure of solitary form of gonadotropin-releasing hormone (GnRH) in cichlid pituitary; three forms of GnRH in brain of cichlid and pumpkinseed fish

1 reference

https://api.crossref.org/works/10.1016%2FS0196-9781%2899%2900130-8

7 January 2021

The effects of gonadotrophin releasing hormone analogues in prostate cancer are mediated through specific tumour receptors

1 reference

https://api.crossref.org/works/10.1016%2FS0196-9781%2899%2900130-8

7 January 2021

Inhibition of prostate tumor growth in two rat models by chronic administration of D-Trp6 analogue of luteinizing hormone-releasing hormone

1 reference

https://api.crossref.org/works/10.1016%2FS0196-9781%2899%2900130-8

7 January 2021

Inhibition of mammary tumor growth in rats and mice by administration of agonistic and antagonistic analogs of luteinizing hormone-releasing hormone

1 reference

https://api.crossref.org/works/10.1016%2FS0196-9781%2899%2900130-8

7 January 2021

Long-acting delivery systems for peptides: inhibition of rat prostate tumors by controlled release of [D-Trp6]luteinizing hormone-releasing hormone from injectable microcapsules

1 reference

https://api.crossref.org/works/10.1016%2FS0196-9781%2899%2900130-8

7 January 2021

Development and applications of luteinizing hormone-releasing hormone antagonists in the treatment of infertility: an overview

1 reference

https://api.crossref.org/works/10.1016%2FS0196-9781%2899%2900130-8

7 January 2021

New effective gonadotropin releasing hormone antagonists with minimal potency for histamine release in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0196-9781%2899%2900130-8

7 January 2021

Endocrine treatment of breast cancer in women

1 reference

https://api.crossref.org/works/10.1016%2FS0196-9781%2899%2900130-8

7 January 2021

LH-RH analogues: I. Their impact on reproductive medicine

1 reference

https://api.crossref.org/works/10.1016%2FS0196-9781%2899%2900130-8

7 January 2021

Isolation and properties of the FSH and LH-releasing hormone

1 reference

https://api.crossref.org/works/10.1016%2FS0196-9781%2899%2900130-8

7 January 2021

Gonadotropin-releasing hormone: one polypeptide regulates secretion of luteinizing and follicle-stimulating hormones

1 reference

https://api.crossref.org/works/10.1016%2FS0196-9781%2899%2900130-8

7 January 2021

Hypothalamic Follicle-Stimulating Hormone (FSH) and Luteinizing Hormone (LH)-Regulating Hormone: Structure, Physiology, and Clinical Studies**The work described here has been supported by research grants from the Veterans Administration, United State

1 reference

https://api.crossref.org/works/10.1016%2FS0196-9781%2899%2900130-8

7 January 2021

FSH-releasing hormone and LH-releasing hormone.

1 reference

https://api.crossref.org/works/10.1016%2FS0196-9781%2899%2900130-8

7 January 2021

The privileges of a Nobel laureate

1 reference

https://api.crossref.org/works/10.1016%2FS0196-9781%2899%2900130-8

7 January 2021

Cancer chemotherapy based on targeting of cytotoxic peptide conjugates to their receptors on tumors.

1 reference

https://api.crossref.org/works/10.1016%2FS0196-9781%2899%2900130-8

7 January 2021

Direct effects of luteinizing hormone-releasing hormone agonists and antagonists on MCF-7 mammary cancer cells

1 reference

https://api.crossref.org/works/10.1016%2FS0196-9781%2899%2900130-8

7 January 2021

Clinical study of leuprolide depot formulation in the treatment of advanced prostate cancer. The Leuprolide Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0196-9781%2899%2900130-8

7 January 2021

Inhibition of growth of human mammary tumor cells by potent antagonists of luteinizing hormone-releasing hormone

1 reference

https://api.crossref.org/works/10.1016%2FS0196-9781%2899%2900130-8

7 January 2021

Treatment of true precocious puberty with a potent luteinizing hormone-releasing factor agonist: effect on growth, sexual maturation, pelvic sonography, and the hypothalamic-pituitary-gonadal axis

1 reference

https://api.crossref.org/works/10.1016%2FS0196-9781%2899%2900130-8

7 January 2021

Growth inhibition of mouse MXT mammary tumor by the luteinizing hormone-releasing hormone antagonist SB-75

1 reference

https://api.crossref.org/works/10.1016%2FS0196-9781%2899%2900130-8

7 January 2021

Inhibitory effects of analogs of luteinizing hormone-releasing hormone and somatostatin on pancreatic cancers in hamsters. Events that accompany tumor regression

1 reference

https://api.crossref.org/works/10.1016%2FS0196-9781%2899%2900130-8

7 January 2021

Effect of combination treatment with analogs of luteinizing hormone-releasing hormone (LH-RH) or somatostatin and 5-fluorouracil on pancreatic cancer in hamsters

1 reference

https://api.crossref.org/works/10.1016%2FS0196-9781%2899%2900130-8

7 January 2021

Targeted cytotoxic luteinizing hormone releasing hormone (LH-RH) anlalogs inhibit growth of estrogen independent MXT mouse mammary cancers in vivo by decreasing cell proliferation and inducing apoptosis

1 reference

https://api.crossref.org/works/10.1016%2FS0196-9781%2899%2900130-8

7 January 2021

Tumor growth inhibition in patients with prostatic carcinoma treated with luteinizing hormone-releasing hormone agonists

1 reference

https://api.crossref.org/works/10.1016%2FS0196-9781%2899%2900130-8

7 January 2021

Induction of azoospermia in normal men with combined Nal-Glu gonadotropin-releasing hormone antagonist and testosterone enanthate

1 reference

https://api.crossref.org/works/10.1016%2FS0196-9781%2899%2900130-8

7 January 2021

Subtle progesterone rise after the administration of the gonadotrophin-releasing hormone antagonist cetrorelix in intracytoplasmic sperm injection cycles

1 reference

https://api.crossref.org/works/10.1016%2FS0196-9781%2899%2900130-8

7 January 2021

Comparison of the potential for therapeutic utilities with gonadotropin-releasing hormone agonists and antagonists

1 reference

https://api.crossref.org/works/10.1016%2FS0196-9781%2899%2900130-8

7 January 2021

Preliminary endocrinological evaluation of a sustained-release formulation of the LH-releasing hormone agonist D-Ser(But)6Azgly10LHRH in premenopausal women with advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0196-9781%2899%2900130-8

7 January 2021

Ovarian hyperstimulation for in-vitro fertilization controlled by GnRH agonist administered in combination with human menopausal gonadotrophins

1 reference

https://api.crossref.org/works/10.1016%2FS0196-9781%2899%2900130-8

7 January 2021

The use of an LH-RH agonist (ICI 118630, Zoladex) in advanced premenopausal breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0196-9781%2899%2900130-8

7 January 2021

Inhibition of growth of OV-1063 human epithelial ovarian cancer xenografts in nude mice by treatment with luteinizing hormone-releasing hormone antagonist SB-75.

1 reference

https://api.crossref.org/works/10.1016%2FS0196-9781%2899%2900130-8

7 January 2021

Inhibitory effect of bombesin/gastrin-releasing peptide antagonist RC-3095 and luteinizing hormone-releasing hormone antagonist SB-75 on the growth of MCF-7 MIII human breast cancer xenografts in athymic nude mice

1 reference

https://api.crossref.org/works/10.1016%2FS0196-9781%2899%2900130-8

7 January 2021

Anovulatory effect of a LHRH antagonist in women

1 reference

https://api.crossref.org/works/10.1016%2FS0196-9781%2899%2900130-8

7 January 2021

Never on a Sunday: programming for IVF-ET and GIFT

1 reference

https://api.crossref.org/works/10.1016%2FS0196-9781%2899%2900130-8

7 January 2021

10.1016/S0196-9781(99)00130-8

Identifiers

DOI

1 reference

29 July 2017

1 reference